Li Shuqing, Yi Zhihui, Li Mingqing, Zhu Zhiling
Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 128 Shenyang Road, Shanghai, 200090, China.
Sci Rep. 2024 Mar 11;14(1):5884. doi: 10.1038/s41598-024-53172-3.
The aim of the present study was to investigate whether a combination of chemotherapy plus radiotherapy was able to increase the overall survival rates compared with chemotherapy alone in stage IB-III uterine serous carcinoma. A total of 1096 patients (593 who had not received radiotherapy, and 503 who had) with primary stage IB-III uterine serous carcinoma who underwent surgery and received chemotherapy were included in the present study. The Kaplan-Meier method and Log-Rank tests showed that radiotherapy did not increase 5-year overall survival rates compared with the no-radiotherapy groups (52.3 cf. 50.8%, respectively; P = 0.641). Cox regression analysis subsequently corroborated that radiotherapy did not affect the 5-year overall survival rate (P = 0.635). Patients who were aged ≥ 60 years had a higher mortality rate [hazard ratio (HR), 1.712; 95% confidence interval (95% CI), 1.385-2.117; P < 0.05]. The 5-year overall survival rates were found to be lower in the groups where the regional lymph nodes had not been removed (HR 0.645; 95% CI 0.508-0.821; P < 0.05). Chemotherapy plus radiotherapy was found to not be associated with improved 5-year overall survival rates. However, chemotherapy may be a better treatment option for patients with primary stage IB-III uterine serous carcinoma who have undergone surgery.
本研究的目的是调查与单纯化疗相比，化疗联合放疗是否能够提高IB-III期子宫浆液性癌患者的总生存率。本研究纳入了1096例接受手术和化疗的原发性IB-III期子宫浆液性癌患者（593例未接受放疗，503例接受了放疗）。Kaplan-Meier法和Log-Rank检验显示，与未放疗组相比，放疗并未提高5年总生存率（分别为52.3%和50.8%；P = 0.641）。随后的Cox回归分析证实，放疗不影响5年总生存率（P = 0.635）。年龄≥60岁的患者死亡率更高[风险比（HR），1.712；95%置信区间（95%CI），1.385 - 2.117；P < 0.05]。未切除区域淋巴结的组5年总生存率较低（HR 0.645；95%CI 0.508 - 0.821；P < 0.05）。发现化疗联合放疗与5年总生存率的改善无关。然而，对于接受手术的原发性IB-III期子宫浆液性癌患者，化疗可能是更好的治疗选择。
